Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

Purification, characterization, and drug susceptibility of tubulin from Leishmania.

Werbovetz KA, Brendle JJ, Sackett DL.

Mol Biochem Parasitol. 1999 Jan 5;98(1):53-65.

PMID:
10029309
2.

Cellular effects of leishmanial tubulin inhibitors on L. donovani.

Havens CG, Bryant N, Asher L, Lamoreaux L, Perfetto S, Brendle JJ, Werbovetz KA.

Mol Biochem Parasitol. 2000 Oct;110(2):223-36.

PMID:
11071278
4.

Effect of the microtubule stabilising agent taxol on leishmanial protozoan parasites in vitro.

Kapoor P, Sachdeva M, Madhubala R.

FEMS Microbiol Lett. 1999 Jul 15;176(2):429-35.

5.
6.

Leishmania tarentolae: purification and characterization of tubulin and its suitability for antileishmanial drug screening.

Yakovich AJ, Ragone FL, Alfonzo JD, Sackett DL, Werbovetz KA.

Exp Parasitol. 2006 Dec;114(4):289-96. Epub 2006 Jun 5.

7.

Antileishmanial dinitroaniline sulfonamides with activity against parasite tubulin.

Bhattacharya G, Salem MM, Werbovetz KA.

Bioorg Med Chem Lett. 2002 Sep 2;12(17):2395-8.

PMID:
12161141
8.
9.

Selective antimicrotubule activity of N1-phenyl-3,5-dinitro-N4,N4-di-n-propylsulfanilamide (GB-II-5) against kinetoplastid parasites.

Werbovetz KA, Sackett DL, Delfín D, Bhattacharya G, Salem M, Obrzut T, Rattendi D, Bacchi C.

Mol Pharmacol. 2003 Dec;64(6):1325-33.

PMID:
14645662
10.

A novel alkyl phosphocholine-dinitroaniline hybrid molecule exhibits biological activity in vitro against Leishmania amazonensis.

Godinho JL, Georgikopoulou K, Calogeropoulou T, de Souza W, Rodrigues JC.

Exp Parasitol. 2013 Sep;135(1):153-65. doi: 10.1016/j.exppara.2013.06.015. Epub 2013 Jul 8.

PMID:
23845259
11.

Tubulin as a target for anticancer drugs: agents which interact with the mitotic spindle.

Jordan A, Hadfield JA, Lawrence NJ, McGown AT.

Med Res Rev. 1998 Jul;18(4):259-96. Review.

PMID:
9664292
13.

Altered transport properties of pentamidine-resistant Leishmania donovani and L. amazonensis promastigotes.

Basselin M, Lawrence F, Robert-Gero M.

Parasitol Res. 1997;83(5):413-8.

PMID:
9197387
14.

Targeting the Cytochrome bc1 Complex of Leishmania Parasites for Discovery of Novel Drugs.

Ortiz D, Forquer I, Boitz J, Soysa R, Elya C, Fulwiler A, Nilsen A, Polley T, Riscoe MK, Ullman B, Landfear SM.

Antimicrob Agents Chemother. 2016 Jul 22;60(8):4972-82. doi: 10.1128/AAC.00850-16. Print 2016 Aug.

15.
17.

Synthesis and biological evaluation of trifluralin analogues as antileishmanial agents.

Esteves MA, Fragiadaki I, Lopes R, Scoulica E, Cruz ME.

Bioorg Med Chem. 2010 Jan 1;18(1):274-81. doi: 10.1016/j.bmc.2009.10.059. Epub 2009 Oct 31.

PMID:
19926293
18.

Rhizoxin binding to tubulin at the maytansine-binding site.

Takahashi M, Iwasaki S, Kobayashi H, Okuda S, Murai T, Sato Y.

Biochim Biophys Acta. 1987 Dec 7;926(3):215-23.

PMID:
3120782
19.
20.

Perifosine Mechanisms of Action in Leishmania Species.

López-Arencibia A, Martín-Navarro C, Sifaoui I, Reyes-Batlle M, Wagner C, Lorenzo-Morales J, Maciver SK, Piñero JE.

Antimicrob Agents Chemother. 2017 Mar 24;61(4). pii: e02127-16. doi: 10.1128/AAC.02127-16. Print 2017 Apr.

Supplemental Content

Support Center